Literature DB >> 21152413

Time will tell: community acceptability of HIV vaccine research before and after the "Step Study" vaccine discontinuation.

Paula M Frew1, Mark J Mulligan, Su-I Hou, Kayshin Chan, Carlos del Rio.   

Abstract

OBJECTIVE: This study examines whether men-who-have-sex-with-men (MSM) and transgender (TG) persons' attitudes, beliefs, and risk perceptions toward human immunodeficiency virus (HIV) vaccine research have been altered as a result of the negative findings from a phase 2B HIV vaccine study.
DESIGN: We conducted a cross-sectional survey among MSM and TG persons (N = 176) recruited from community settings in Atlanta from 2007 to 2008. The first group was recruited during an active phase 2B HIV vaccine trial in which a candidate vaccine was being evaluated (the "Step Study"), and the second group was recruited after product futility was widely reported in the media.
METHODS: Descriptive statistics, t tests, and chi-square tests were conducted to ascertain differences between the groups, and ordinal logistic regressions examined the influences of the above-mentioned factors on a critical outcome, future HIV vaccine study participation. The ordinal regression outcomes evaluated the influences on disinclination, neutrality, and inclination to study participation.
RESULTS: Behavioral outcomes such as future recruitment, event attendance, study promotion, and community mobilization did not reveal any differences in participants' intentions between the groups. However, we observed greater interest in HIV vaccine study screening (t = 1.07, P < 0.05) and enrollment (t = 1.15, P < 0.05) following negative vaccine findings. Means on perceptions, attitudes, and beliefs did not differ between the groups. Before this development, only beliefs exhibited a strong relationship on the enrollment intention (β = 2.166, P = 0.002). However, the effect disappeared following negative trial results, with the positive assessment of the study-site perceptions being the only significant contributing factor on enrollment intentions (β = 1.369, P = 0.011).
CONCLUSION: Findings show greater enrollment intention among this population in the wake of negative efficacy findings from the Step Study. The resolve of this community to find an HIV vaccine is evident. Moreover, any exposure to information disseminated in the public arena did not appear to negatively influence the potential for future participation in HIV vaccine studies among this population. The results suggest that subsequent studies testing candidate vaccines could be conducted in this population.

Entities:  

Year:  2010        PMID: 21152413      PMCID: PMC2996614          DOI: 10.2147/OAJCT.S11915

Source DB:  PubMed          Journal:  Open Access J Clin Trials        ISSN: 1179-1519


  23 in total

1.  The cognitive impact of past behavior: influences on beliefs, attitudes, and future behavioral decisions.

Authors:  D Albarracín; R S Wyer
Journal:  J Pers Soc Psychol       Date:  2000-07

2.  Who will enroll? Predicting participation in a phase II AIDS vaccine trial.

Authors:  S D Halpern; D S Metzger; J A Berlin; P A Ubel
Journal:  J Acquir Immune Defic Syndr       Date:  2001-07-01       Impact factor: 3.731

3.  A venue-based method for sampling hard-to-reach populations.

Authors:  F B Muhib; L S Lin; A Stueve; R L Miller; W L Ford; W D Johnson; P J Smith
Journal:  Public Health Rep       Date:  2001       Impact factor: 2.792

4.  HIV vaccine trial participation among ethnic minority communities: barriers, motivators, and implications for recruitment.

Authors:  Peter A Newman; Naihua Duan; Kathleen J Roberts; Danielle Seiden; Ellen T Rudy; Dallas Swendeman; Svetlana Popova
Journal:  J Acquir Immune Defic Syndr       Date:  2006-02-01       Impact factor: 3.731

5.  Enrollment of racial/ethnic minorities in NIAID-funded networks of HIV vaccine trials in the United States, 1988 to 2002.

Authors:  Gaston Djomand; Joanna Katzman; Dante di Tommaso; Michael G Hudgens; George W Counts; Beryl A Koblin; Patrick S Sullivan
Journal:  Public Health Rep       Date:  2005 Sep-Oct       Impact factor: 2.792

6.  Feasibility and suitability of targeting young gay men for HIV vaccine efficacy trials.

Authors:  S Scheer; J M Douglas; E Vittinghoff; B N Bartholow; D McKirnan; F N Judson; K M MacQueen; S Buchbinder
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1999-02-01

7.  An extended model of reasoned action to understand the influence of individual- and network-level factors on African Americans' participation in HIV vaccine research.

Authors:  Paula M Frew; Matthew Archibald; Dazon Dixon Diallo; Su-I Hou; Takeia Horton; Kayshin Chan; Mark J Mulligan; Carlos del Rio
Journal:  Prev Sci       Date:  2010-06

8.  Correlates of negative intent to receive an AIDS vaccine: an exploratory study.

Authors:  Richard A Crosby; David R Holtgrave; Lawrence Bryant; Paula M Frew
Journal:  Int J STD AIDS       Date:  2004-08       Impact factor: 1.359

9.  Understanding differences in enrollment outcomes among high-risk populations recruited to a phase IIb HIV vaccine trial.

Authors:  Paula M Frew; Carlos del Rio; Lu Lu; Sarah Clifton; Mark J Mulligan
Journal:  J Acquir Immune Defic Syndr       Date:  2009-03-01       Impact factor: 3.731

10.  Enrolling women into HIV preventive vaccine trials: an ethical imperative but a logistical challenge.

Authors:  Edward Mills; Stephanie Nixon; Sonal Singh; Sonam Dolma; Anjali Nayyar; Sushma Kapoor
Journal:  PLoS Med       Date:  2006-02-21       Impact factor: 11.069

View more
  3 in total

1.  "Once Bitten, Twice Shy": participant perspectives in the aftermath of an early HIV vaccine trial termination.

Authors:  P A Newman; S Yim; A Daley; R Walisser; R Halpenny; W Cunningham; M Loutfy
Journal:  Vaccine       Date:  2010-11-12       Impact factor: 3.641

2.  Clinical trials: innovation, progress and controversy.

Authors:  Greg S Martin
Journal:  Open Access J Clin Trials       Date:  2011-08

3.  Representation of Latinos and Blacks in screening for and enrollment into preventive HIV vaccine trials in New York City.

Authors:  Tanya M Ellman; Kellie Hawkins; Jorge Benitez; Ramon Negron; Steven Chang; Steven Palmer; Verna Robertson; Mary Ann Chiasson; Magdalena E Sobieszczyk
Journal:  Vaccine       Date:  2015-10-11       Impact factor: 3.641

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.